4 recruiting. 4 Phase 1, 2 Phase 2.
| Phase | Trials | Status |
|---|---|---|
| Phase 1 | 4 | Recruiting 4 |
| Phase 2 | 2 | Recruiting 2 |
Follow NHL: new trials by email Literature Review of NHL trials Research Report on NHL
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| A Study to Assess PK, Safety and Efficacy of HSK47977 Tablets in Subjects With Relapsed or Refractory Non-Hodgkin's Lymphoma HSK47977 - NHL | Phase 1 | Recruiting | Haisco Pharmaceutical Group Co., Ltd. | 110 | 2025-08-28 | 2025-12-19 |
| A Phase 1 Study of FD-001 in Recurrent /Refractory (R/R)AML/NHL/MM/MDS FD-001 - AML, NHL | Phase 1 | Recruiting | Chengdu FenDi Pharmaceutical Co., Ltd. | 72 | 2024-03-11 | 2024-12-17 |
| IDP-023 as a Single Agent and in Combination With Antibody Therapies in Patients With Advanced Hematologic Cancers IDP-023, Rituximab, Daratumumab - NHL, Multiple Myeloma | Phase 1 / Phase 2 | Recruiting | Indapta Therapeutics, INC. | 128 | 2023-10-25 | 2025-06-03 |
| Assessment of Safety and Efficacy of IM19 for Recurrent or Refractory (R/R) Non-Hodgkin's Lymphoma(NHL) Patients IM19 CAR-T Cells - NHL | Phase 1 / Phase 2 | Recruiting | Beijing Immunochina Medical Science & Technology Co., Ltd. | 52 | 2020-06-04 | 2020-12-08 |
Hematologic Neoplasms (1) · Lymphoma, Non-Hodgkin (1) · Multiple Myeloma (1)
Blood Protein Disorders (1) · Cardiovascular Diseases (1) · Hematologic Diseases (1) · Hemic and Lymphatic Diseases (1) · Hemorrhagic Disorders (1) · Hemostatic Disorders (1) · Immune System Diseases (1) · Immunoproliferative Disorders (1) · Lymphatic Diseases (1) · Lymphoma (1) · Lymphoproliferative Disorders (1) · Neoplasms (1) · Neoplasms by Histologic Type (1) · Neoplasms by Site (1) · Neoplasms, Plasma Cell (1)
Cyclophosphamide (2) · fludarabine (2) · Interleukin-2 (1) · Mesna (1) · Rituximab (1) · aldesleukin (1) · daratumumab (1) · isatuximab (1)
Beijing Immunochina Medical Science & Technology Co., Ltd. (1) · Chengdu FenDi Pharmaceutical Co., Ltd. (1) · Haisco Pharmaceutical Group Co., Ltd. (1) · Indapta Therapeutics, INC. (1)
China (3) · United States (1)